Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Huland

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
World Journal of Urology|May 26, 2001
Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancerH Heinzer, E Huland, H Huland
Der Urologe. Ausg. A|August 25, 2000
[Treatment of metastatic renal cell carcinoma. Value of immunotherapy compared with surgery of metastases]H Heinzer, E Huland, H Huland
The Journal of Urology|February 1, 1992
Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinomaE Huland, H Huland, H Heinzer
Cancer Research|May 1, 1986
Human transitional cell carcinoma in the NMRI-nu/nu mouse bladder: a new animal model for the in vivo use of monoclonal antibodies and cytotoxic agentsE Huland, R Arndt, H Huland
Cancer Immunology, Immunotherapy : CII|May 24, 2000
Local cytokine therapy of cancer: interleukin-2, interferons and related cytokinesJ Bubeník, W Den Otter, E Huland
Anticancer Research|September 2, 1999
Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growthS H Hautmann, E Huland, H Huland
European Urology|January 1, 1993
Virus-related serology and in situ hybridization for the detection of virus DNA among patients with testicular cancerH Heinzer, K P Dieckmann, E Huland
Der Urologe. Ausg. A|September 1, 1989
[Quantitative immunocytology as a marker for indications and follow-up of recurrence prevention of superficial urinary bladder cancers]A W Schneider, E Huland, H Huland
The Journal of Urology|September 1, 1990
Quantitative immunocytology in the management of patients with superficial bladder carcinoma. I. A marker to identify patients who do not require prophylaxisE Huland, H Huland, A W Schneider
International Journal of Oncology|April 30, 2011
Immunocytologic staining of cytokeratin in bone marrow aspirates to detect micrometastatic cells fails in patients with metastatic urologic carcinomaH Schwaibold, S Wenck, E Huland, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
World Journal of Urology|May 26, 2001
Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancerH Heinzer, E Huland, H Huland
Der Urologe. Ausg. A|August 25, 2000
[Treatment of metastatic renal cell carcinoma. Value of immunotherapy compared with surgery of metastases]H Heinzer, E Huland, H Huland
The Journal of Urology|February 1, 1992
Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinomaE Huland, H Huland, H Heinzer
Cancer Research|May 1, 1986
Human transitional cell carcinoma in the NMRI-nu/nu mouse bladder: a new animal model for the in vivo use of monoclonal antibodies and cytotoxic agentsE Huland, R Arndt, H Huland
Cancer Immunology, Immunotherapy : CII|May 24, 2000
Local cytokine therapy of cancer: interleukin-2, interferons and related cytokinesJ Bubeník, W Den Otter, E Huland
Anticancer Research|September 2, 1999
Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growthS H Hautmann, E Huland, H Huland
European Urology|January 1, 1993
Virus-related serology and in situ hybridization for the detection of virus DNA among patients with testicular cancerH Heinzer, K P Dieckmann, E Huland
Der Urologe. Ausg. A|September 1, 1989
[Quantitative immunocytology as a marker for indications and follow-up of recurrence prevention of superficial urinary bladder cancers]A W Schneider, E Huland, H Huland
The Journal of Urology|September 1, 1990
Quantitative immunocytology in the management of patients with superficial bladder carcinoma. I. A marker to identify patients who do not require prophylaxisE Huland, H Huland, A W Schneider
International Journal of Oncology|April 30, 2011
Immunocytologic staining of cytokeratin in bone marrow aspirates to detect micrometastatic cells fails in patients with metastatic urologic carcinomaH Schwaibold, S Wenck, E Huland, et al.
Pageof 6